The FDA‐approved first‐line drugs for HCC patients, sorafenib and lenvatinib, extends HCC patient survival for only several months.[2] Recently, clinical trial results indicated combination treatment of atezolizumab (anti‐PD‐L1) and bevacizumab (anti‐VEGF) achieved improved overall and progression‐free survival benefits compared to sorafenib treatment.[3] Cancer cells have high adaptability to depletion of different nutrients by flexibly rewiring their metabolic programs. This evidence concerns the gene VEGFA and hepatocellular carcinoma.